GlassScriptPhysician profile
Zahid Saqib
NPI 1710063292
$1,556.23
in general payments reported to CMS, 2019-2025
17 companies · $64.27 in 2025
The $64.27 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $336 · 2021: $504 · 2022: $58.81 · 2023: $14.85 · 2024: $58.25 · 2025: $64.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $228.61 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $206.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $174.07 | 2019-2021 | |
| Glaxosmithkline, LLC. | $173.04 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $163.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $136.08 | 2019-2020 | |
| Pfizer INC. | $123.02 | 2019-2021 | |
| Mylan Specialty L.P. | $84.85 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $56.10 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Kowa Pharmaceuticals America, INC. | $43.60 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $41.93 | 2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $34.93 | 2020 | |
| Sunovion Pharmaceuticals INC. | $26.11 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $25.47 | 2024 | Crysvita |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $12.19 | 2022 | |
| Astellas Pharma US INC | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zahid Saqib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.